(Total Views: 350)
Posted On: 05/10/2021 10:10:07 AM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Perhaps the rationale for additional leonlimab dosages when treating S/C COVID patients should be that a large number of those patients who were saved after the initial treatment still have a deadly form of "long haulers disease". A condition which was not envisioned when the first trials were designed.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)